State-Of-The-Art Human Gene Therapy: Part II. Gene Therapy Strategies and Clinical Applications

被引:0
作者
Wang, Dan [1 ]
Gao, Guangping [1 ,2 ,3 ]
机构
[1] Univ Massachusetts, Sch Med, Gene Therapy Ctr, Worcester, MA 01605 USA
[2] Univ Massachusetts, Sch Med, Dept Microbiol & Physiol Syst, Worcester, MA 01605 USA
[3] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu 610064, Sichuan, Peoples R China
基金
美国国家卫生研究院;
关键词
LEBER CONGENITAL AMAUROSIS; ENGINEERED NUCLEASES; IMMUNE-RESPONSES; RPE65; MUTATIONS; VECTORS; PROGRESS; AUGMENTATION; CONSTRUCTS; PROTECTION; INFECTION;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
In Part I of this Review (Wang and Gao, 2014), we introduced recent advances in gene delivery technologies and explained how they have powered some of the current human gene therapy applications. In Part II, we expand the discussion on gene therapy applications, focusing on some of the most exciting clinical uses. To help readers to grasp the essence and to better organize the diverse applications, we categorize them under four gene therapy strategies: (1) gene replacement therapy for monogenic diseases, (2) gene addition for complex disorders and infectious diseases, (3) gene expression alteration targeting RNA, and (4) gene editing to introduce targeted changes in host genome. Human gene therapy started with the simple idea that replacing a faulty gene with a functional copy can cure a disease. It has been a long and bumpy road to finally translate this seemingly straightforward concept into reality. As many disease mechanisms unraveled, gene therapists have employed a gene addition strategy backed by a deep knowledge of what goes wrong in diseases and how to harness host cellular machinery to battle against diseases. Breakthroughs in other biotechnologies, such as RNA interference and genome editing by chimeric nucleases, have the potential to be integrated into gene therapy. Although clinical trials utilizing these new technologies are currently sparse, these innovations are expected to greatly broaden the scope of gene therapy in the near future.
引用
收藏
页码:151 / 161
页数:11
相关论文
共 70 条
[31]   Treatment of Leber Congenital Amaurosis Due to RPE65 Mutations by Ocular Subretinal Injection of Adeno-Associated Virus Gene Vector: Short-Term Results of a Phase I Trial [J].
Hauswirth, William W. ;
Aleman, Tomas S. ;
Kaushal, Shalesh ;
Cideciyan, Artur V. ;
Schwartz, Sharon B. ;
Wang, Lili ;
Conlon, Thomas J. ;
Boye, Sanford L. ;
Flotte, Terence R. ;
Byrne, Barry J. ;
Jacobson, Samuel G. .
HUMAN GENE THERAPY, 2008, 19 (10) :979-990
[32]   Current status of haemophilia gene therapy [J].
High, K. H. ;
Nathwani, A. ;
Spencer, T. ;
Lillicrap, D. .
HAEMOPHILIA, 2014, 20 :43-49
[33]   Enhancement of SMN2 Exon 7 inclusion by antisense oligonucleotides targeting the exon [J].
Hua, Yimin ;
Vickers, Timothy A. ;
Baker, Brenda F. ;
Bennett, C. Frank ;
Krainer, Adrian R. .
PLOS BIOLOGY, 2007, 5 (04) :729-744
[34]   Gene Therapy for Leber Congenital Amaurosis Caused by RPE65 Mutations Safety and Efficacy in 15 Children and Adults Followed Up to 3 Years [J].
Jacobson, Samuel G. ;
Cideciyan, Artur V. ;
Ratnakaram, Ramakrishna ;
Heon, Elise ;
Schwartz, Sharon B. ;
Roman, Alejandro J. ;
Peden, Marc C. ;
Aleman, Tomas S. ;
Boye, Sanford L. ;
Sumaroka, Alexander ;
Conlon, Thomas J. ;
Calcedo, Roberto ;
Pang, Ji-Jing ;
Erger, Kirsten E. ;
Olivares, Melani B. ;
Mullins, Cristina L. ;
Swider, Malgorzata ;
Kaushal, Shalesh ;
Feuer, William J. ;
Iannaccone, Alessandro ;
Fishman, Gerald A. ;
Stone, Edwin M. ;
Byrne, Barry J. ;
Hauswirth, William W. .
ARCHIVES OF OPHTHALMOLOGY, 2012, 130 (01) :9-24
[35]   Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) A Phase 2 Trial of Intracoronary Gene Therapy of Sarcoplasmic Reticulum Ca2+-ATPase in Patients With Advanced Heart Failure [J].
Jessup, Mariell ;
Greenberg, Barry ;
Mancini, Donna ;
Cappola, Thomas ;
Pauly, Daniel F. ;
Jaski, Brian ;
Yaroshinsky, Alex ;
Zsebo, Krisztina M. ;
Dittrich, Howard ;
Hajjar, Roger J. .
CIRCULATION, 2011, 124 (03) :304-U113
[36]   Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys [J].
Johnson, Philip R. ;
Schnepp, Bruce C. ;
Zhang, Jianchao ;
Connell, Mary J. ;
Greene, Sean M. ;
Yuste, Eloisa ;
Desrosiers, Ronald C. ;
Clark, K. Reed .
NATURE MEDICINE, 2009, 15 (08) :901-U99
[37]   INNOVATION TALENs: a widely applicable technology for targeted genome editing [J].
Joung, J. Keith ;
Sander, Jeffry D. .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2013, 14 (01) :49-55
[38]   Membrane-binding and enzymatic properties of RPE65 [J].
Kiser, Philip D. ;
Palczewski, Krzysztof .
PROGRESS IN RETINAL AND EYE RESEARCH, 2010, 29 (05) :428-442
[39]   Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors [J].
Kochenderfer, James N. ;
Rosenberg, Steven A. .
NATURE REVIEWS CLINICAL ONCOLOGY, 2013, 10 (05) :267-276
[40]   Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19 [J].
Kochenderfer, James N. ;
Wilson, Wyndham H. ;
Janik, John E. ;
Dudley, Mark E. ;
Stetler-Stevenson, Maryalice ;
Feldman, Steven A. ;
Maric, Irina ;
Raffeld, Mark ;
Nathan, Debbie-Ann N. ;
Lanier, Brock J. ;
Morgan, Richard A. ;
Rosenberg, Steven A. .
BLOOD, 2010, 116 (20) :4099-4102